Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 3 2Phase 1 1

Status

Completed 4Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 5Observational 2

Sponsor

Conditions

Lymphoma, Large B-Cell, Diffuse 413Lymphoma 401Lymphoma, Non-Hodgkin 337Leukemia, Lymphocytic, Chronic, B-Cell 302Lymphoma, Follicular 295Lymphoma, Mantle-Cell 225Lymphoma, B-Cell, Marginal Zone 159Leukemia 119Lymphoma, B-Cell 112Burkitt Lymphoma 110Waldenstrom Macroglobulinemia 99Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Recurrence 83Hodgkin Disease 60Lymphoma, Large-Cell, Immunoblastic 57Neoplasms 39Multiple Myeloma 26Lymphoma, Large-Cell, Anaplastic 26Myelodysplastic Syndromes 25Leukemia, Myeloid, Acute 24Dendritic Cell Sarcoma, Interdigitating 22Hematologic Neoplasms 21Leukemia, Hairy Cell 20Intraocular Lymphoma 17Leukemia, Prolymphocytic 16Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, T-Cell 14Neoplasms, Plasma Cell 13Lymphoproliferative Disorders 12Hematologic Diseases 12

Interventions

Adalimumab 13Methotrexate 11Etanercept 10Rituximab 5Abatacept 5tocilizumab 4olokizumab 4tofacitinib 3golimumab 3Infliximab 3Tumor Necrosis Factor Inhibitors 2Saline Solution 2RC-18 2Nivolumab 2Leflunomide 2Certolizumab Pegol 2Antirheumatic Agents 2veltuzumab 1upadacitinib 1secukinumab 1sarilumab 1mavrilimumab 1entecavir 1cabozantinib 1baricitinib 1andecaliximab 1Vitamin D 1Vaccines 1TACI receptor-IgG Fc fragment fusion protein 1Syringes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Arthritis, Rheumatoid × Rituximab × Clear all
NCT06175338 2024-09-19

Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis

Mabscale, LLC

Phase 1 Active not recruiting
208 enrolled

Arthritis, Rheumatoid

NCT00503425 2017-08-15

A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

Hoffmann-La Roche

Phase 3 Completed
215 enrolled 9 charts

Arthritis, Rheumatoid

NCT01295151 2016-11-02

SWITCH

University of Leeds

Phase 4 Completed
122 enrolled

Arthritis, Rheumatoid

NCT00468546 2016-10-25

A Study to Evaluate the Safety and Efficacy of MabThera (Rituximab) in Combination With Methotrexate (MTX) in Participants With Active Rheumatoid Arthritis Who Failed on Anti-Tumor Necrosis Factor Alpha Therapy

Hoffmann-La Roche

Phase 3 Completed
520 enrolled 17 charts

Arthritis, Rheumatoid

NCT01593332 2012-05-08

Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis

Mashhad University of Medical Sciences

Phase 4 Completed
44 enrolled

Arthritis, Rheumatoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡